1109.0000 5.20 (0.47%)
NSE Apr 02, 2026 15:31 PM
Volume: 42,786
 

1109.00
0.47%
ICICI Securities Limited
Tatva Chintan’s Q2FY23 revenue fell 27.1% YoY and EBITDA plunged 68.9% YoY due
to lower SDA sales, which seems very disappointing, but we believe this situation is
transitory.
Tatva Chintan Pharma Chem Ltd. is trading below all available SMAs
More from Tatva Chintan Pharma Chem Ltd.
Recommended